©Reuters.
CAMBRIDGE, Mass. – Centogene NV (NASDAQ:CNTG), a life sciences company specializing in rare and neurodegenerative diseases, today announced that it is evaluating strategic alternatives to enhance shareholder value.
The company, known for its expertise in complex disease diagnostics and pharmaceutical services, is evaluating various options, including mergers, acquisitions, divestitures, partnerships, additional financing or continuation as an independent entity.
The decision to explore these alternatives comes after Centogene made significant progress in 2023, launching new genomic products and establishing a joint venture in Saudi Arabia for genetic testing services. Despite this progress, the company recognizes the challenges posed by current financial markets and aims to position itself for sustained growth and profitability.
Kim Stratton, CEO of Centogene, said that management, in collaboration with the Supervisory Board, is evaluating the available options. A special committee of independent members was appointed to oversee this strategic review, with the assistance of a consultancy firm.
Centogene’s mission is to provide life-changing, data-driven answers to patients and the pharmaceutical industry through its multiomics technologies and extensive biological database. The company has built a network of approximately 30,000 active physicians since its founding in 2006 and has contributed to more than 285 peer-reviewed publications.
This announcement is based on a press release.
This article was generated with the support of AI and reviewed by an editor. For further information please see our T&Cs.